MiMedx Group (MDXG) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avita Medical (RCEL) has outperformed MiMedx Group (MDXG) over the past year, gaining 312.1% versus a loss of 54.9%. Over five years, RCEL leads with a +10.8% price change compared with -58.6% for MDXG. Avita Medical is the larger company by market cap ($495.0 million vs $445.1 million), about 1.1 times the size, while MiMedx Group is growing revenue faster (+20.0% vs +11.5%).
MiMedx Group converts more of its revenue into profit, with a net margin of 11.6% versus -67.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | RCEL |
|---|---|---|
| Share price | $3.05 | $15.62 |
| Market cap | $445.07M | $494.96M |
| 1-day change | -1.93% | -2.31% |
| YTD return | -54.95% | +352.75% |
| 1-year return | -54.88% | +312.14% |
| 5-year return | -58.62% | +10.78% |
| Forward P/E | 122.00 | — |
| EPS (TTM) | $-0.13 | $-1.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $418.63M | $71.61M |
| Revenue growth (YoY) | +19.99% | +11.45% |
| Net income (latest FY) | $48.58M | $-48.59M |
| Gross margin | 82.56% | 82.13% |
| Operating margin | 15.26% | -59.40% |
| Net margin | 11.60% | -67.85% |
| 52-week high | $7.45 | $18.43 |
| 52-week low | $3.03 | $3.22 |
| Distance from 52-week high | -59.06% | -15.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +129.51% | +32.46% |
| Average volume | 1.39M | 417.02K |
| Shares outstanding | 145.93M | 31.69M |
| Employees | 808 | 226 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed MDXG by 367.0 percentage points over the past year.
- MiMedx Group is more profitable, keeping 11.6 cents of every revenue dollar as net income versus -67.8 cents for Avita Medical.
- MiMedx Group grew revenue faster in its latest fiscal year (+19.99% vs +11.45%).
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
MDXG vs RCEL FAQ
Which is bigger, MiMedx Group or Avita Medical?
Avita Medical (RCEL) is larger, with a market capitalization of $494.96M compared with $445.07M for MiMedx Group (MDXG).
Which stock has performed better over the past year, MDXG or RCEL?
RCEL returned +312.14% over the past 12 months, compared with -54.88% for MDXG (price return, excluding dividends). Past performance does not predict future results.
Are MiMedx Group and Avita Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.